ANVS SHAREHOLDER CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.
2 min read
fairly difficult
NEW YORK, NY / ACCESSWIRE / September 27, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to...
file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Annovis Bio, Inc.. ("Annovis Bio" or the "Company") (NYSE:ANVS) from May 21, 2021 through July 28, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Eastern District of Pennsylvania alleges violations of the Securities Act of 1934.

If you purchased Annovis Bio securities, and/or would like to discuss your legal rights and options please visit Annovis Bio Shareholder Class Action Lawsuit or contact Rujul Patel toll free at (877) 779-1414 or

The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements as well as failed to disclose adverse facts about the Company's business, operations, and prospects.

On July 28, 2021, after the market closed, the Company announced that its Alzheimer's and Parkinson's drug, Posiphen, failed to show statistically significant success relative to the placebo in clinical…
Read full article